CRISPR Therapeutics (CRSP) Tops Q1 EPS by 107c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($0.67), $1.07 better than the analyst estimate of ($1.74). Revenue for the quarter came in at $100 million versus the consensus estimate of $25.85 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Paramount Global (PARA) Tops Q2 EPS by 480c